Cosmo Pharmaceuticals N.V. reiterated earnings guidance for the Year 2023 . For the year, company expects total revenue between EUR 110 million and EUR 120 million, operating profit between EUR 25 million and EUR 35 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.9 CHF | -0.83% | -0.55% | +41.26% |
04-26 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
04-25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.26% | 1.29B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023